MMAF Inhibitor – Sodium

Name: MMAF Inhibitor; Sodium; MyBioSource
Brand: MyBioSource
SKU: MBS5755220
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755220

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

MMAF sodium, Inhibitor

Full Product Name

MMAF sodium

Product Gene Name

MMAF, inhibitor

Product Synonym Names

Monomethylauristatin F sodium

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

753.94

Solubility

DMSO: 200mg/mL (265.27mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C39H64N5NaO8

SMILES

CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C([O-])=O)CC2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O)C.[Na+]

CAS Number

1799706-65-2

Target & IC50

Auristatin

In Vitro

MMAF suppresses anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O, and Caki-1 cells. It has IC50s of 119, 105, 257, and 200nM in vitro cytotoxicity assay[4].

Product Categories/Family for MMAF, inhibitor

Membrane transporter/Ion channel; ABC; Others

Product References and Citations for MMAF, inhibitor

Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.
Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.
Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.

Other Notes

Small volumes of MMAF, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for MMAF purchase

MBS5755220 is an inhibitor targeting MMAF. Also known as MMAF sodium.